Gene: PLD3

23646
AD19|HU-K4|HUK4|SCA46
phospholipase D family member 3
protein-coding
19q13.2
Ensembl:ENSG00000105223 MIM:615698 Vega:OTTHUMG00000152736 UniprotKB:Q8IV08
NG_034098.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.359e-1 (AD)  6.866e-2 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMEM59L0.979
BSCL20.978
SLC22A170.978
OTUB10.976
MAPRE30.974
EEF1A20.972
GSK3A0.972
AP2M10.971
ATP6V0D10.971
PRKAR1B0.968

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.712
OR4F29-0.667
REST-0.43
RAI14-0.409
TFPI2-0.4
KCNJ15-0.393
CXCR2-0.382
FCGR3B-0.378
WWTR1-0.376
CNN2-0.376

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0299552-nitrotoluene2-nitrotoluene results in increased expression of PLD3 mRNA15612046
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLD3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLD3 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of PLD3 mRNA26690555
D000082AcetaminophenAcetaminophen results in increased expression of PLD3 mRNA22230336
D000082AcetaminophenAcetaminophen affects the expression of PLD3 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of PLD3 mRNA23630614
C006632arsenic trioxidearsenic trioxide results in decreased expression of PLD3 mRNA22521957
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PLD3 mRNA20106945
D004958EstradiolEstradiol results in increased expression of PLD3 mRNA15289156
C006780bisphenol Abisphenol A results in increased expression of PLD3 mRNA29275510
C006780bisphenol Abisphenol A results in increased expression of PLD3 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PLD3 mRNA28628672
C584509C646 compoundC646 compound results in increased expression of PLD3 mRNA26191083
D002104CadmiumCadmium results in decreased expression of PLD3 mRNA24084258
D003513CycloheximideCycloheximide results in increased expression of PLD3 mRNA19684285
D003513Cycloheximide[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA19684285
D003561CytarabineCytarabine results in decreased expression of PLD3 mRNA21198554
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of PLD3 mRNA24317228
D003907DexamethasoneDexamethasone results in decreased expression of PLD3 mRNA25047013
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PLD3 mRNA28628672
D015946Ethylene DibromideEthylene Dibromide results in increased expression of PLD3 mRNA15612046
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of PLD3 mRNA21266533
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of PLD3 mRNA27392435
D002945CisplatinCisplatin results in increased expression of PLD3 mRNA27392435
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of PLD3 mRNA14648872|1528915
D004298DopamineDopamine affects the expression of PLD3 protein24675778
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of PLD3 mRNA23649840
C082360fipronilfipronil results in decreased expression of PLD3 mRNA23962444
D019833GenisteinGenistein results in increased expression of PLD3 mRNA15289156
C004312glycidolglycidol results in increased expression of PLD3 mRNA15612046
C492448ICG 001ICG 001 results in increased expression of PLD3 mRNA26191083
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PLD3 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of PLD3 mRNA28628672
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of PLD3 mRNA27392435
C544151jinfukangjinfukang results in increased expression of PLD3 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of PLD3 mRNA24796395
C410337K 7174K 7174 results in increased expression of PLD3 mRNA24086573
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of PLD3 mRNA"24972896
D058185Magnetite Nanoparticles[Succimer binds to Magnetite Nanoparticles] which results in increased expression of PLD3 mRNA21641980
D008727MethotrexatePLD3 protein affects the susceptibility to Methotrexate16217747
C036868methyl carbamatemethyl carbamate results in increased expression of PLD3 mRNA15612046
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of PLD3 mRNA"20188158
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of PLD3 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of PLD3 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of PLD3 mRNA"25554681
D009532NickelNickel results in decreased expression of PLD3 mRNA24084258
C028007nickel monoxidenickel monoxide results in increased expression of PLD3 mRNA19167457
C029938nickel sulfatenickel sulfate results in increased expression of PLD3 mRNA18651567
C007350nitrofennitrofen results in decreased expression of PLD3 mRNA20638522
C030110oxaliplatinoxaliplatin results in increased expression of PLD3 mRNA25729387
D052638Particulate MatterParticulate Matter results in increased expression of PLD3 mRNA28412507
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLD3 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of PLD3 mRNA26272509
C014153pirimiphos methylpirimiphos methyl results in decreased expression of PLD3 mRNA27845199
D011192Potassium DichromatePotassium Dichromate results in increased expression of PLD3 protein23718831
D011794QuercetinQuercetin results in increased expression of PLD3 mRNA21632981
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of PLD3 mRNA21427059
D012999SomanSoman results in decreased expression of PLD3 mRNA19281266
D004113Succimer[Succimer binds to Magnetite Nanoparticles] which results in increased expression of PLD3 mRNA21641980
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA19684285
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of PLD3 mRNA19684285
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PLD3 mRNA21570461|2468072
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PLD3 mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of PLD3 mRNA21215274
D013806TheophyllineTheophylline results in increased expression of PLD3 mRNA16083514
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of PLD3 mRNA20133372
D019772TopotecanTopotecan results in increased expression of PLD3 mRNA25729387
D014212TretinoinTretinoin results in increased expression of PLD3 mRNA16054129
C012589trichostatin Atrichostatin A affects the expression of PLD3 mRNA28542535
C012589trichostatin Atrichostatin A results in increased expression of PLD3 mRNA15901671
D014635Valproic AcidValproic Acid results in increased expression of PLD3 mRNA27188386
D014635Valproic AcidValproic Acid results in increased expression of PLD3 mRNA21427059
D014635Valproic AcidValproic Acid results in increased expression of PLD3 mRNA15901671
C025643vinclozolinvinclozolin results in decreased expression of PLD3 mRNA23034163
D024483Vitamin K 3Vitamin K 3 affects the expression of PLD3 mRNA20044591

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004630phospholipase D activity-IEA-  
GO:0005515protein binding-IPI20195357  24336208  
GO:0070290N-acylphosphatidylethanolamine-specific phospholipase D activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0016042lipid catabolic process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005789endoplasmic reticulum membrane-IEA-  
GO:0016021integral component of membrane-IEA-  
GO:0070062extracellular exosome-HDA19056867  19199708  23533145  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismIEA
R-HSA-1483148Synthesis of PGIEA
R-HSA-1483206Glycerophospholipid biosynthesisIEA
R-HSA-1483257Phospholipid metabolismIEA
R-HSA-168249Innate Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-2029480Fcgamma receptor (FCGR) dependent phagocytosisTAS
R-HSA-2029485Role of phospholipids in phagocytosisTAS
R-HSA-556833Metabolism of lipidsIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28199971Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population. (2017 Apr 11)Lin EOncotarget